237 related articles for article (PubMed ID: 25633983)
1. Faldaprevir for the treatment of genotype-1 hepatitis C virus.
Agarwal K; Barnabas A
Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):277-88. PubMed ID: 25633983
[TBL] [Abstract][Full Text] [Related]
2. Faldaprevir for the treatment of hepatitis C.
Kanda T; Yokosuka O; Omata M
Int J Mol Sci; 2015 Mar; 16(3):4985-96. PubMed ID: 25749475
[TBL] [Abstract][Full Text] [Related]
3. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Jensen DM; Asselah T; Dieterich D; Foster GR; Sulkowski MS; Zeuzem S; Mantry P; Yoshida EM; Moreno C; Ouzan D; Wright M; Morano LE; Buynak R; Bourlière M; Hassanein T; Nishiguchi S; Kao JH; Omata M; Paik SW; Wong DK; Tam E; Kaita K; Feinman SV; Stern JO; Scherer J; Quinson AM; Voss F; Gallivan JP; Böcher WO; Ferenci P
Ann Hepatol; 2016; 15(3):333-49. PubMed ID: 27049487
[TBL] [Abstract][Full Text] [Related]
4. Faldaprevir for the treatment of hepatitis C.
Campagna D; Demma S
Drugs Today (Barc); 2015 May; 51(5):289-301. PubMed ID: 26097902
[TBL] [Abstract][Full Text] [Related]
5. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.
Zeuzem S; Asselah T; Angus P; Zarski JP; Larrey D; Müllhaupt B; Gane E; Schuchmann M; Lohse AW; Pol S; Bronowicki JP; Roberts S; Arasteh K; Zoulim F; Heim M; Stern JO; Nehmiz G; Kukolj G; Böcher WO; Mensa FJ
Antivir Ther; 2013; 18(8):1015-9. PubMed ID: 23558093
[TBL] [Abstract][Full Text] [Related]
6. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
[TBL] [Abstract][Full Text] [Related]
8. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
Tornai I
Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
[TBL] [Abstract][Full Text] [Related]
9. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Dieterich D; Nelson M; Soriano V; Arastéh K; Guardiola JM; Rockstroh JK; Bhagani S; Laguno M; Tural C; Ingiliz P; Jain MK; Stern JO; Manero M; Vinisko R; Kort J;
AIDS; 2015 Mar; 29(5):571-81. PubMed ID: 25710287
[TBL] [Abstract][Full Text] [Related]
10. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
11. HCV direct-acting antiviral agents: the best interferon-free combinations.
Schinazi R; Halfon P; Marcellin P; Asselah T
Liver Int; 2014 Feb; 34 Suppl 1(Suppl 1):69-78. PubMed ID: 24373081
[TBL] [Abstract][Full Text] [Related]
12. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.
Nelson DR
Liver Int; 2011 Jan; 31 Suppl 1():53-7. PubMed ID: 21205138
[TBL] [Abstract][Full Text] [Related]
13. [Hepatitis C virus: 25 years-old, the end?].
Pol S
Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
[TBL] [Abstract][Full Text] [Related]
14. Antiviral strategies in hepatitis C virus infection.
Sarrazin C; Hézode C; Zeuzem S; Pawlotsky JM
J Hepatol; 2012; 56 Suppl 1():S88-100. PubMed ID: 22300469
[TBL] [Abstract][Full Text] [Related]
15. Simeprevir for the treatment of chronic hepatitis C.
You DM; Pockros PJ
Expert Opin Pharmacother; 2013 Dec; 14(18):2581-9. PubMed ID: 24138198
[TBL] [Abstract][Full Text] [Related]
16. A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.
Taieb V; Pacou M; Ho S; Pettré S; Van Sanden S; Pisini M; Ustianowski A; Mehnert A
J Med Econ; 2015; 18(10):787-96. PubMed ID: 25934147
[TBL] [Abstract][Full Text] [Related]
17. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.
Pawlotsky JM
Gastroenterology; 2011 Mar; 140(3):746-54. PubMed ID: 21255572
[No Abstract] [Full Text] [Related]
18. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
Ferenci P; Asselah T; Foster GR; Zeuzem S; Sarrazin C; Moreno C; Ouzan D; Maevskaya M; Calinas F; Morano LE; Crespo J; Dufour JF; Bourlière M; Agarwal K; Forton D; Schuchmann M; Zehnter E; Nishiguchi S; Omata M; Kukolj G; Datsenko Y; Garcia M; Scherer J; Quinson AM; Stern JO;
J Hepatol; 2015 Jun; 62(6):1246-55. PubMed ID: 25559324
[TBL] [Abstract][Full Text] [Related]
19. Faldaprevir and deleobuvir for HCV genotype 1 infection.
Zeuzem S; Soriano V; Asselah T; Bronowicki JP; Lohse AW; Müllhaupt B; Schuchmann M; Bourlière M; Buti M; Roberts SK; Gane EJ; Stern JO; Vinisko R; Kukolj G; Gallivan JP; Böcher WO; Mensa FJ
N Engl J Med; 2013 Aug; 369(7):630-9. PubMed ID: 23944300
[TBL] [Abstract][Full Text] [Related]
20. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
Asselah T; Marcellin P
Liver Int; 2014 Feb; 34 Suppl 1():60-8. PubMed ID: 24373080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
